Nan Fung Trinity HK Ltd. Sells 282,474 Shares of Immunome, Inc. $IMNM

Nan Fung Trinity HK Ltd. reduced its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 31.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 621,079 shares of the company’s stock after selling 282,474 shares during the period. Nan Fung Trinity HK Ltd. owned approximately 0.55% of Immunome worth $13,359,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IMNM. Allworth Financial LP acquired a new stake in shares of Immunome in the 2nd quarter valued at $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Immunome during the 2nd quarter worth $27,000. KBC Group NV acquired a new position in shares of Immunome during the 1st quarter worth $60,000. GK Wealth Management LLC acquired a new position in shares of Immunome during the 3rd quarter worth $71,000. Finally, Sterling Capital Management LLC lifted its position in shares of Immunome by 840.0% during the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after buying an additional 3,108 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Truist Financial boosted their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. William Blair started coverage on shares of Immunome in a report on Friday, October 16th. They issued an “outperform” rating for the company. HC Wainwright reissued a “buy” rating on shares of Immunome in a report on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.85.

Immunome Stock Performance

Shares of IMNM opened at $18.70 on Friday. Immunome, Inc. has a 52 week low of $16.11 and a 52 week high of $30.06. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -7.08 and a beta of 2.68. The stock has a fifty day moving average of $20.82 and a 200-day moving average of $22.27.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, equities analysts forecast that Immunome, Inc. will post -2.59 EPS for the current year.

Insider Activity at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the sale, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. The trade was a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company’s stock.

Trending Headlines about Immunome

Here are a few of the latest headlines about IMNM:

• Positive Sentiment: HC Wainwright kept its Buy rating despite reducing its estimates.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.76 from $0.68, and reduced full-year EPS estimates to losses of $2.64 for 2026, $2.71 for 2027, $2.41 for 2028, $1.63 for 2029, and $0.42 for 2030. The largest revisions include turning its 2029 forecast from a $0.40 profit to a loss, and its 2030 forecast from a $1.08 profit to a loss. These changes signal weaker expected earnings. Immunome analyst estimates
• Negative Sentiment: Piper Sandler cut its price target for Immunome. Piper Sandler price target cut

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.